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Background: Conventional treatment for locally advanced rectal cancer usually combines neoadjuvant
radiochemotherapy and surgery. Until recently, there have been limited predictive factors (clinical or biological) for
rectal tumor response to conventional treatment. KRAS, BRAF and PIK3CA mutations are commonly found in colon
cancers. In this study, we aimed to determine the mutation frequencies of KRAS, BRAF and PIK3CA and to establish
whether such mutations may be used as prognostic and/or predictive factors in rectal cancer patients.
Methods: We retrospectively reviewed the clinical and biological data of 98 consecutive operated patients
between May 2006 and September 2009. We focused in patients who received surgery in our center after
radiochemotherapy and in which tumor samples were available.
Results: In the 98 patients with a rectal cancer, the median follow-up time was 28.3 months (4–74). Eight out of
ninety-eight patients experienced a local recurrence (8%) and 17/98 developed distant metastasis (17%). KRAS, BRAF
and PIK3CA were identified respectively in 23 (23.5%), 2 (2%) and 4 (4%) patients. As described in previous studies,
mutations in KRAS and BRAF were mutually exclusive. No patient with local recurrence exhibited KRAS or PIK3CA
mutation and one harbored BRAF mutation (12.5%). Of the seventeen patients with distant metastasis (17%), 5 were
presenting KRAS mutation (29%), one BRAF (5%) and one PIK3CA mutation (5%). No relationship was seen between
PIK3CA, KRAS or BRAF mutation and local or distant recurrences.
Conclusion: The frequencies of KRAS, BRAF and PIK3CA mutations in our study were lower than the average
frequencies reported in colorectal cancers and no significant correlation was found between local/distant
recurrences and KRAS, BRAF or PIK3CA mutations. Future studies with greater number of patients, longer follow-up
time and greater power to predict associations are necessary to fully understand this relationship.Background
Over the last decade, the management of colorectal
cancer (CRC) has progressed faster than in any other
gastrointestinal tumors [1]. These advances have been
made especially in metastatic disease, with the introduc-
tion of targeted therapies in addition to chemotherapy
and the development of metastasis surgery [2-5]. Im-
provements have also been made in the adjuvant setting
with the introduction of the oxaliplatin-based chemo-
therapy regimen in stage III colon cancer [6]. Less* Correspondence: olfa.derbel@lyon.unicancer.fr
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reproduction in any medium, provided the orprogress has been made in the management of rectal
cancer. Radiochemotherapy based on 5FU regimen,
followed by total mesorectum excision (TME) represents
the optimal combined treatment for locally advanced
rectal cancer (defined as T3 and/or N+ disease) [7,8].
Neoadjuvant radiochemotherapy has been shown to
reduce local recurrences and to increase pathological
complete response compared with radiotherapy and
surgery [9-11]. This preoperative modality is currently
preferred to the postoperative one because of a signifi-
cantly lower local recurrence rate, improved sphincter
preservation and less toxicity [12,13]. Attempts to increase
the benefit of radiochemotherapy have been tried, espe-
cially with the introduction of oxaliplatin in addition toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apy has remained the standard treatment for patients with
locally-advanced rectal cancer [9,13-15]. The decision to
use neoadjuvant radiochemotherapy is based on a pre-
treatment tumor staging defining the T and the N stage
with pelvic MRI and endorectal ultrasound. The tumor
response is evaluated by the pathological examination of
the operative specimen. It is well known that downstaging
after radiochemotherapy has been shown to predict fewer
recurrences and better prognosis [13,16]. However, the
decision to use neoadjuvent radiochemotherapy is com-
plex. First, the tumor response can be evaluated only after
the pathological examination. Secondly, despite low local
recurrence rates, patients with initially localized rectal
cancer continue to have high mortality because of se-
condary metastases (15-35%). On the other hand, some
patients may be over treated with radiochemotherapy.
Therefore, many authors have tried to identify predictive
factors to anticipate radiochemotherapy response. Cur-
rently, the best available methods to investigate improved
outcomes in rectal cancer include accurate early assessment
of tumor response with MRI and identifying predictive
molecular tumor abnormalities.
KRAS, BRAF and PIK3CA mutations are commonly
found in colorectal cancers. KRAS and BRAF genes can
harbor oncogenic mutations that yield a constitutively
active protein and are found in approximately 30–50%
and 10–15% of CRC tumors, respectively [17,18]. Several
studies have indicated that the presence of mutant KRAS
in CRC tumors correlates with poor response to EGFR
in a metastatic setting [5,18-20]. Furthermore, BRAF
mutations have been incriminated as poor prognosis
factors in metastatic CRC [21]. However, the impact of
KRAS and BRAF mutations on clinical outcome of
patients with locally advanced CRC are unknown.
Regarding PIK3CA, a large cohort study has recently
shown that PIK3CA mutation was associated with poor
prognosis among patients with resectable stage I to III
colon cancer [22]. Another large population-based study
in colon cancer suggested that the activation of the
PI3K/AKT or the RAS-RAF-MAPK pathway by muta-
tion of at least one of the three genes predicted poor pa-
tient outcome, but the effect of mutations in PIK3CA
alone was not discussed [17]. Another previous study of
a small cohort of colorectal cancer patients reported that
PIK3CA mutation is predictive of poor survival [23].
Recently, He et al. showed that PIK3CA mutations were
strongly associated with a high risk of local recurrences
in non irradiated stage I to III rectal cancer patients
[24]. As their population was heterogeneous in tumor
stage (I to III) and was not treated with combined
modality therapy, we aimed to corroborate the mutation
frequencies of KRAS, BRAF and PIK3CA in rectal cancer
and to establish whether such mutations may be used asprognostic and/or predictive factors in multimodal
treated rectal cancer patients. This study is the first to
look at all three mutations in locally advanced rectal
(not colorectal) cancer in patients treated with neoad-
juvent chemotherapy and surgery.
Methods
Patients and tumor samples
The clinical records of all consecutively patients with locally
advanced rectal carcinoma (clinical T3 or T4 or node-
positive) referred to the Centre Leon Berard between May
2006 and September 2009 were reviewed. The study was
approved by the ethic committee of Leon Berard Center.
Written informed consent was obtained for all patients.
The inclusion criteria were a confirmed diagnosis of
rectal adenocarcinoma and available tumor sample. All
patients gave their informed consent for this research.
Diagnosis was established on the basis of histological fea-
tures and was confirmed by immunochemical staining.
Pathology procedures were standardized and quality con-
trolled. Prior to treatment, a history and physical exam
were completed for all patients as well as assessment of
performance status, complete blood counts (CBCs), liver
function creatinine, and serum carcinoembryogenic anti-
gen. All patients underwent before treatment a rigid
rectoscopy and a total colonoscopy. Tumor and nodal
stage was evaluated with pelvic MRI and/or an endorectal
ultrasound. Metastatic extension was eliminated with a
chest- abdomen-pelvis computed tomography. Clinical
tumor staging was finally defined with the “i” (MRI) or “u”
(ultrasound) tumor-node-metastasis (TNM) classification.
Clinical examination and CBCs were repeated every week
during radiochemotherapy. Four weeks after the end of ra-
diochemotherapy, clinical tumor stage was re-evaluated
with pelvic MRI and CT. After surgery, patients were
assessed every 3 months during the first two years and
every 6 months during years 3 to 5.
Patients were treated with neoadjuvant radiochemo-
therapy and TME-surgery. Radiotherapy consisted on 45
to 50 Gy in 25 fractions of 1.8 to 2Gy with concurrent
intravenous 5FU or capecitabine. Oral capecitabine 800
mg/m2 twice daily was started on the first day of radio-
therapy and given 5 days per week during radiotherapy.
When used, infusional 5FU was given at a dose of
350 mg/m2/d from Monday to Friday with leucovorin at
a dose of 20 mg/m2/d. Surgery was planned 6 weeks
after the end of preoperative radiochemotherapy. Total
mesorectal excision was performed according to a stan-
dardized technique.
DNA extraction and mutation analysis
DNA was amplified with specific primers for exons where
"hot-spot" mutations are located. DNA was extracted from
FFPE primary tumor samples using QIAamp DNA FFPE
Table 1 Clinical and molecular characteristics of 98
patients with rectal carcinoma
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KRAS gene (exon 2 and 3), PIK3CA gene (exon 9 and
exon 20), BRAF gene (exon 15), was investigated by PCR
amplification followed by direct sequencing using ABI
3730 automated sequencer (life Technologies). The oligo
sequences of primers used for analyses are available upon
request.Age. y median 68 (35–88)
Distance to anal verge. cm
≥10 25 (25.5)
5≤ <10 26 (26.5)
<5 40 (41.8)
Not avaibale 7 (7.2)
Type of resection
Low anterior 8 (8.1)Statistical analysis
All statistical analyses were done with SPSS statistical
software (version 15.0 for Windows, SPSS, Inc). χ2 test
and Fisher's exact test were used to compare proportions.
Recurrences and survival analyses were done using the
Kaplan-Meier method with time of surgery as entry date.










Ninety-eight consecutive patients treated at the Centre
Leon Berard, Lyon, France for an advanced rectal cancer
between May 2006 and September 2009 met the
inclusion criteria. Locally advanced rectal cancer was
defined as T3 and/or N+ disease with pelvic MRI and/or
endorectal ultrasound. Median follow-up was 28.3 months












We correlated the KRAS, BRAF and PIK3CA genotypes
with clinicopathological features of CRC, including pri-
mary tumour location, histological findings, and sites of
metastases. There was no correlation between mutations
and clinicopathologic features, including age, gender,
tumor location, type of resection, circumferential margin
(CRM), differentiation grade, lymph node and TNM stage.
We also investigated whether KRAS, BRAF or PIK3CA
mutations may confer radioresistance and reduced res-
ponse to CRT. There was no difference in residual tumor
status or in response to chemoradiation as assessed by







Positive 17 (17.4)Mutation analysis
KRAS, BRAF and PIK3CA were identified respectively in
23 (23.5%), 2 (2%) and 4 (4%) patients. The most
frequent mutation at KRAS was G13D which accounted
for 43% of KRAS mutations (10/23). The codon 12
mutations were the G12D (5/23), G12V (4/23), G12S
(2/23), G12R (1/23) and G12C (1/23). BRAF V600E
mutation was identified in one patient (50%). Mutations
are summarized in Table 1 and the distribution of the
mutations is shown in Figure 1. As described in previous













Figure 1 The distribution of mutations is illustrated in a pie chart.
Table 3 Mutational status and metastatic recurrence




Non 63 (77.8%) 12 (70.6%) 75 (76.5%)
Yes 18 (22.2%) 5 (29.4%) 23 (23.5%)
BRAF mutation Fisher Exact
P = 0.318
Non 80 (98.8%) 16 (94.1%) 96 (98.0%)
Yes 1 (1.2%) 1 (5.9%) 2 (2.0%)
PIK3CA mutation Fisher Exact
P = 0.539
Non 78 (96.3%) 16 (94.1%) 94 (95.9%)






No 61 (75.3%) 11 (64.7%) 72 (73.5%)
Yes 20 (24.7%) 6 (35.3%) 26 (26.5%)
Nb of mutations Fisher Exact
P = 0.462
0 61 (75.3%) 11 (64.7%) 72 (73.5%)
1 18 (22.2%) 5 (29.4%) 23 (23.5%)
2 2 (2.5%) 1 (5.9%) 3 (3.1%)
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With a median follow-up time of 28.3 months (4–74), 8
patients experienced a local recurrence (8%) and 17
developed distant metastasis (17%). No patient with local
recurrence exhibited KRAS or PIK3CA mutation and one
harbored BRAF mutation (12.5%). Among the seventeen
patients (17%) with distant metastasis, 5 were harboring
KRAS mutation (29%), one BRAF (5%) and one KRAS
mutation (5%). Survival analyses compared results for
patients with each mutation, patients with at least one of
the 3 mutations versus those who had no mutations





No 67 (74.4%) 8 (100.0%) 75 (76.5%)
yes 23 (25.6%) 0 (0.0%) 23 (23.5%)
BRAF Mutation
No 89 (98.9%) 7 (87.5%) 96 (98.0%)
yes 1 (1.1%) 1 (12.5%) 2 (2.0%)
PIK3CA Mutation
No 86 (95.6%) 8 (100.0%) 94 (95.9%)
yes 4 (4.4%) 0 (0.0%) 4 (4.1%)
All mutations
At least one mutation
No 65 (72.2%) 7 (87.5%) 72 (73.5%)
yes 25 (27.8%) 1 (12.5%) 26 (26.5%)
Nb of mutations
0 65 (72.2%) 7 (87.5%) 72 (73.5%)
1 22 (24.4%) 1 (12.5%) 23 (23.5%)
2 3 (3.3%) 0 (0.0%) 3 (3.1%)No relationship was seen between PIK3CA, KRAS or
BRAF mutation and local or distant recurrences and no
longer with overall survival (all p< 0.01).
Discussion
Despite the recent advances in the management of meta-
static colorectal cancer (mCRC) over the last few years,
this disease remains a major public health problem in
the world [1]. Its prognosis has been improved, but
recurrences remain a clinical challenge. Local recur-
rences are a critical issue in rectal cancer and several
tumor characteristics are associated with local recur-
rence, including depth of tumour invasion into and
beyond the bowel wall, number of lymph nodes involved
by tumor cells, extramural venous invasion, involvement
of the circumferential resection margin (CRM) and the
tumor location within 10 cm from anal verge. These
factors may be used in therapeutic decisions regarding
administration of (neo) adjuvant treatment [25]. However,
patients with similar clinicopathologic characteristics still
display a large variation in prognosis, suggesting that the
biology of the tumor may be responsible for the difference.
The detection of biological predictive markers may
improve the selection of patients who will benefit from
(neo) adjuvant treatment and spare patients who will only
experience side effects. The MAPK pathway plays a major
role in cell proliferation and is involved in up to 30% of
CRC [26]. Both KRAS and BRAF are the members of this
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oncogenic mutations. KRAS mutations, are reported in 19
to 48% of patients with rectal cancer [1,24-27], whereas
BRAF mutations are found in 0 to 12% of RC patients
[28,29]. The mutation frequency reported in our study
(23% for KRAS and 2% for BRAF) are in concordance with
those reported in literature. The rarity of V600E BRAF
mutations in rectal cancer has been previously described
in reports from Di Nicolantonio et al. [30] who found 1
V600E allele in 43 rectal samples and Fransen et al. [28]
who even found 2 mutations in 55 rectal cancers.
In our study, we identified a 4% incidence for PIK3CA
mutations, which is lower than the 10% to 30% reported
in colon cancer. The first study in colorectal cancer
reported that PIK3CA mutations were significantly
associated with poor survival [23]. They further iden-
tified PIK3CA mutations as the only independent and
significant prognostic factor for relapse-free survival in
stage II to III patients. However, there were only 18
PIK3CA-mutated tumors and the number of deaths was
not reported. Another study has shown that the presence
of at least one mutation in PIK3CA, BRAF, or KRAS genes
predicts poor survival in a population-based colon cancer
samples, however, the effect of PIK3CA mutations on
survival, independently of clinical and other molecular
predictors of outcome, was not described [31]. In a recent
study, Ogino et al. examined the prognostic significance of
PIK3CA mutations among 450 patients who had under-
gone a curative resection of colon cancer. They found that
PIK3CA mutations were associated with a decreased sur-
vival. The “poor prognosis” effect of PIK3CA mutations
seemed to be robust and consistent across most strata of
clinical and tumoral predictors of patient outcome, but
this effect seems to be limited to patients with KRAS wild-
type tumors [22]. Additionally, these mutation studies
make no distinction between rectal and colic cancer. A
recent study determined the prognostic value of PIK3CA
mutations in 240 non- irradiated resectable stages I to III
rectal cancer patients from the Dutch TME trial. PIK3CA
mutations were identified in 19 (7.9%) of the 240 patients
and revealed a strong association with an increased local
recurrence rate. Moreover, tumors with PIK3CA muta-
tions showed a tendency to develop local recurrences
more rapidly after surgery [24].
A second analysis by He et al. was published in 2010
concerning the results in irradiated patients from the
total mesorectal excision (TME) trial. In this population,
they investigated whether PIK3CA mutant patients
benefit from preoperative radiotherapy. Although the
difference was not statistically significant, it suggests that
PIK3CA mutant patients seem to benefit from irradiation
in preventing LR [32].
Several studies have focused on KRAS mutation and
radioresistance, with controversial conclusions. Michelassiet al. found that tumor downstaging was associated with
KRAS wild type tumors [33] and Grana et al. reported that
KRAS mutations potentially mediate resistance to ionizing
radiation [34]. Other studies reported no change in
downstaging by KRAS status [29,35,36] and even when
adjusting the groups according to the codon which carried
the mutation, failed to predict response to preoperative
CT/RT. In a recent study, Davies showed that KRAS
mutational status was not associated with radiosensitivity
using more modern sequencing technology in a larger
number of patients than previously described [37]. Inter-
estingly, they reported that activation of AKT and ERK is
correlated with response to radiation therapy [37].
Conclusions
In summary, our retrospective study failed to confirm a
significant correlation between KRAS, BRAF or PIK3CA
mutations as predictive factors of local or distant recur-
rence, following preoperative RT/CT. The exact effects of
KRAS, BRAF and PIK3CA mutations on recurrence require
further study with analyses of a larger patient population
because the number of relapse events was very small and
may represent a sample bias. Finally, the follow-up period
was probably too short to draw definitive conclusions.
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